ClinicalTrials.gg
Not yet recruitingNCT06917014Updated May 16, 2025

Hysteroscopic "360°" Surgery for Improvement of Symptoms in Cesarean Scar Defects

An interventional study of 360° and traditional in Cesarean Scar Defect, sponsored by Fu Xing Hospital, Capital Medical University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Fu Xing Hospital, Capital Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Patients with symptomatic Cesarean Scar Defect (CSD) who are expected to undergo hysteroscopic surgery will be randomly divided into the traditional hysteroscopic "channelization" treatment group and the hysteroscopic "360 °" Surgery group of cesarean diverticulum, and the improvement of postoperative clinical symptoms of the two groups will be compared. To evaluate the effectiveness of the two surgical methods.

The purpose of this study was to evaluate the improvement of symptoms of women with symptomatic cesarean diverticulum through a high-quality randomized controlled study, in order to provide high-level evidence-based medical evidence for clinical treatment.

Read the detailed description
  1. Study Design:This is a prospective, randomized controlled trial.
  2. Study population 120 patients diagnosed with Cesarean Scar Defect (CSD) will be prospectively recruited. Before the surgery all patients will undergo preoperative evaluations, including a detailed history of the menstrual pattern,any previous History of cesarean section, and reproductive history, as well as trans-vaginal ultrasonography and Three-dimensional SIS Ultrasound.
  3. Randomization:

    Randomization was performed electronically using SPSS statistical software version 26.0 (SPSS, Inc., Chicago, IL,USA) by the investigator.120 recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: the control group("channelization" group) and the experimental group("360°" group).

  4. Surgical technique:

    Hysteroscopic surgery will be performed in a standardized manner.The procedure will be performed under general anesthesia. Ultrasonographic guidance will be routinely used.

    The interference of "360°" group (the experimental group) including 60 CSD patients ,With the vaginoscopic approach, the isthmocele was localized; a high-frequency 90°angled circular loop electrode and pure cutting current of 100 W were used to resect the fibrotic tissue of the proximal (step 1) and distal (step 2) part of the niche. The investigators performed resection not only of the fibrotic tissue underneath the niche but also of the inflamed tissue placed around the niche and on the opposite site (the so-called channel-like 360° endocervical ablation). A high-frequency angled ball electrode was used to obtain focused coagulation of all residual inflamed tissue still present on the niche surface and on the cervical canal walls (step 3); the aim of this step is to facilitate the re-epithelialization of the cervical canal walls by the paraphysiological endocervical epithelium. The procedure was ended by controlling any bleeding of the endocervical vessels by reducing the inflow and pressure of the distending medium and by focused electrocauterization with a ball electrode (step 4).while the interference of "channelization" group (the control group) , With the vaginoscopic approach, the isthmocele was localized; a high-frequency 90°angled circular loop electrode and pure cutting current of 100 W were used to resect the fibrotic tissue of the proximal perform intrauterine adhesiolysis with bipolar electric needle electrode, part of the scar tissue removed by electronic loop when it is necessary.A angled ball electrode was used to obtain focused coagulation of proliferating blood vessels, inflammatory tissue, and ectopic endometrium in the diverticulum.In both arms, the endometrium tissue was removed and sent to pathology, followed by immunohistochemical CD138 examination

  5. Postoperative treatments All subjects will be treated with oral antibiotics for 3 days. Three-dimensional SIS Ultrasound will be carried out 3 months after the surgery.
  6. Follow up:

    Follow-up styles: the doctor's outpatient review, patients fill in questionnaires,telephone, WeChat and so on.

    Follow-up time:3 months and 6 months after the operation. Follow-up contents: the data measured by 3D-SIS,At the same time, the endometrium was taken again for immunohistochemical CD138 examination. Assessed the improvement of symptoms, including the improvement of prolonged menstrual period, the improvement of heavy menstruation, and the patient's postoperative satisfaction.

  7. Consent: All subjects will be given a detailed explanation of the study and sufficient time to consider their participation. A written consent form will be signed by the patient and retained in the records.
02

Conditions studied

  • Cesarean Scar Defect

Browse trials for

Keywords

  • Hysteroscopic "360°" Surgery
  • Cesarean Scar Defects
03

In context

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

This study's planned enrollment of 88 is above the median of 40 across 515 interventional studies indexed under Cicatrix.

Browse Cicatrix studies →

Lead sponsor

Fu Xing Hospital, Capital Medical University is the lead sponsor of 17 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with surgical adaptation: changes in menstruation after cesarean section (prolonged menstrual period)
  • No surgical ;
  • Age 18-45 years old;
  • The thickness of residual muscle layer measured by ultrasound is greater than or equal to 2.5mm;
  • Patients with symptoms that have not improved significantly for more than 1 month after oral short-acting cycle treatment or who strongly require surgery;
  • Understand and agree to the research plan.

Exclusion criteria

Exclusion Criteria:

  • Patients with other diseases that may cause abnormal uterine bleeding (including endometrial polyps, endometrial hyperplasia, submucosal myoma, etc.) indicated by two-dimensional ultrasound
  • There are of surgery: such as severe internal and surgical complications, pregnancy, reproductive tract infection, malignant tumor;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    360°

    The interference of the experimental group is to resect the fibrotic inflamed tissue of the proximal and distal part of the niche, a high-frequency angled ball electrode was used to obtain focused coagulation of all residual inflamed tissue still present on the niche surface and on the cervical canal walls, focused electrocauterization with a ball electrode controlling any bleeding of the endocervical vessels.

    Procedure: 360°

  • Other
    traditional

    The interference of the control group is to resect the fibrotic tissue of the proximal of the niche, use angled ball electrode coagulation.

    Procedure: traditional

Interventions

  • Procedure360°

    reset the proximal and distal part of the niche, widely 360° coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.

  • Proceduretraditional

    reset the proximal part of the niche, and coagulation to restore and change the shape and size of niche, and ultimately improve symptoms of patients.

06

What researchers measure

Primary outcomes

  1. Symptom change rate

    Rate of change in abnormal bleeding before and after the operation

    Time frame: 6 months after surgery

Secondary outcomes

  1. Ultrasound measurement values

    Ultrasound measurement values before and after the operation,include residual muscle thickness;length of cesarean scar defects;width of cesarean scar defects;height of cesarean scar defects

    Time frame: 3 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Casadio P, Gubbini G, Morra C, Franchini M, Paradisi R, Seracchioli R. Channel-like 360 degrees Isthmocele Treatment with a 16F Mini-Resectoscope: A Step-by-step Technique. J Minim Invasive Gynecol. 2019 Nov-Dec;26(7):1229-1230. doi: 10.1016/j.jmig.2019.04.024. Epub 2019 May 3. PubMed 31059782 ↗
  • Casadio P, Raffone A, Alletto A, Filipponi F, Raimondo D, Arena A, La Rosa M, Virgilio A, Franceschini C, Gubbini G, Franchini M, Paradisi R, Lenzi J, Travaglino A, Mollo A, Carugno J, Seracchioli R. Postoperative morphologic changes of the isthmocele and clinical impact in patients treated by channel-like (360 degrees ) hysteroscopic technique. Int J Gynaecol Obstet. 2023 Jan;160(1):326-333. doi: 10.1002/ijgo.14387. Epub 2022 Aug 23. PubMed 35929843 ↗
  • Zhang NN, Wang GW, Yang Q. Endoscopic Treatment of Previous Cesarean Scar Defect in Women with Postmenstrual Bleeding: A Retrospective Cohort Study. J Invest Surg. 2021 Oct;34(10):1147-1155. doi: 10.1080/08941939.2020.1766161. Epub 2020 May 13. PubMed 32404009 ↗
  • Shapira M, Mashiach R, Meller N, Watad H, Baron A, Bouaziz J, Cohen SB. Clinical Success Rate of Extensive Hysteroscopic Cesarean Scar Defect Excision and Correlation to Histologic Findings. J Minim Invasive Gynecol. 2020 Jan;27(1):129-134. doi: 10.1016/j.jmig.2019.03.001. Epub 2019 Mar 8. PubMed 30858053 ↗
  • He Y, Zhong J, Zhou W, Zeng S, Li H, Yang H, Shan N. Four Surgical Strategies for the Treatment of Cesarean Scar Defect: A Systematic Review and Network Meta-analysis. J Minim Invasive Gynecol. 2020 Mar-Apr;27(3):593-602. doi: 10.1016/j.jmig.2019.03.027. Epub 2019 Nov 5. PubMed 31698049 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Nov 2029, 54 months later.

Of 175 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 54 months is above that.

Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 8 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 8, 2025
StartEst.
May 16, 2025
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06917014
Lead sponsor
Fu Xing Hospital, Capital Medical University
Responsible party
Xiaowu Huang (Director of department, Fu Xing Hospital, Capital Medical University) — Principal investigator
First posted
Apr 8, 2025
Start date
May 16, 2025 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
May 16, 2025

Study contacts

Xiaowu Huang
Contact
hxiaowu_fxyy@126.com
+8613810828816

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion